Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
The VZN and ZEN studies are non-comparative trials assessing triple combination therapy comprising thymidine and non-thymidine analogue nucleoside reverse transcriptase inhibitors plus a protease inhibitor. Preliminary data are available for the VZN study and recruitment for the ZEN study is underway.